Africa’s largest drug company, Aspen Pharmacare, has written down the value of a heartburn medicine it sells primarily in Australia by R719m after it was recalled due to possible cancer risks.

The company’s full-year results to end-June have been restated on a “worst-case basis” after Australian regulators ordered the recall of all products containing ranitidine, which contains a by-product that may pose a low carcinogenic risk from long-time exposure...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now